For example, etanercept (a TNF-α antagonist decoy receptor) was beneficial for patients with low plasma levels of IL6 and interferon (IFN)γ (34), but it exacerbated MG in a patient with RA (35) and also reactivated tuberculosis (36, 37). This evidence concerns the gene IFNG and myasthenia gravis.